Since my last Eli Lilly (NYSE: LLY ) (NEOE: LLY:CA ) analysis , the stock has gained 9% in price. I anticipate broader healthcare momentum to build in 2026. This is still an optimal entry point.Analyst’s Disclosure:I/we have a beneficial long position in the shares of LLY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any ...